Eledon Pharmaceuticals, Inc.

Stage 4 · Declining · week 2

As of Oct 22, 2026, Eledon Pharmaceuticals is in Stage 4, the downtrend phase, now in week 2 (since Oct 9, 2026). It closed at $2.30, 47.2% below its 52-week high and below its 200-day average, which is rising.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. More about the company

$2.30

+1.77% today

$187M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ELDN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 29w

S2 19w

S2 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 8w → S1 4w → S4 7w → S1 5w → S2 29w → S3 3w → S2 2w → S3 3w → S2 19w → S3 7w → S4 11w → S1 5w → S4 10w → S1 4w → S4 11w → S1 8w → S2 17w → S3 9w → S4 2w current

Total tracked: 165 weeks across 19 stage runs.

ELDN among Biotechnology296th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…296	ELDNEledon Pharmaceuticals, Inc.	Stage 4 · wk 2	31	−15.4%

vs 52W High

-47.2%

$1.39 lo$4.36 hi

47.2% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 2

1w13w26w

Week 2, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-25.4%

200 DMA: $3.08 · rising

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.59x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-15.4%

-35.8%

-35.9%

YTD

+42.0%

-34.1%

Scan Membership

Breakout Watch

Latest: 2024-10-25

6 appearances in last 60 days. First seen: 2019-04-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 2 · Vol 0.59x

2026-10-21S4

Wk 2 · Vol 0.65x

2026-10-20S4

Wk 2 · Vol 0.82x

2026-10-19S4

Wk 2 · Vol 1.17x

2026-10-16S4

Wk 2 · Vol 0.90x

2026-10-15S4

Wk 1 · Vol 0.65x

2026-10-14S4

Wk 1 · Vol 1.11x

2026-10-13S4

Wk 1 · Vol 1.30x

2026-10-12S4

Wk 1 · Vol 0.49x

2026-10-09S43→4

Wk 1 · Vol 0.90x

2026-10-08S3

Wk 9 · Vol 0.91x

2026-10-07S3

Wk 9 · Vol 0.63x

Moving averages & range

50 DMA

$2.81

200 DMA

$3.08

52W High

$4.36

52W Low

$1.39

5D Low

$2.13

Resistance levels (recent highs)

20d High

$2.65

60d High

$3.77

120d High

$4.21

250d High

$4.36

Next resistance

+15.2%

to 20d High

ROE

-110.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.6

Eledon Pharmaceuticals: quick answers

What stage is Eledon Pharmaceuticals in?

As of Oct 22, 2026, Eledon Pharmaceuticals (ELDN) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 9, 2026 and is in week 2. What the four stages mean

Is Eledon Pharmaceuticals in an uptrend?

No. Eledon Pharmaceuticals is in a Stage 4 downtrend. It trades 25.4% below its 200-day average, which is rising.

How far is Eledon Pharmaceuticals from its 52-week high?

Eledon Pharmaceuticals closed at $2.30 on Oct 22, 2026, 47.2% below its 52-week high of $4.36. Its 52-week low is $1.39.

How has Eledon Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Eledon Pharmaceuticals is down 34.1% over the past year and up 42.0% so far in 2026.

Which sector and industry is Eledon Pharmaceuticals in?

Eledon Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.